Strs Ohio lifted its position in Collegium Pharmaceutical Inc (NASDAQ:COLL) by 51.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 50,800 shares of the specialty pharmaceutical company’s stock after acquiring an additional 17,300 shares during the period. Strs Ohio’s holdings in Collegium Pharmaceutical were worth $748,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in COLL. Millennium Management LLC raised its position in shares of Collegium Pharmaceutical by 1,171.8% in the 2nd quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock worth $8,611,000 after acquiring an additional 332,647 shares in the last quarter. BlackRock Inc. raised its position in shares of Collegium Pharmaceutical by 13.8% in the 2nd quarter. BlackRock Inc. now owns 2,252,273 shares of the specialty pharmaceutical company’s stock worth $53,717,000 after acquiring an additional 272,302 shares in the last quarter. Macquarie Group Ltd. raised its position in shares of Collegium Pharmaceutical by 9.9% in the 2nd quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock worth $61,732,000 after acquiring an additional 233,598 shares in the last quarter. Northern Trust Corp raised its position in shares of Collegium Pharmaceutical by 78.5% in the 2nd quarter. Northern Trust Corp now owns 526,499 shares of the specialty pharmaceutical company’s stock worth $12,557,000 after acquiring an additional 231,463 shares in the last quarter. Finally, Highland Capital Management LP raised its position in shares of Collegium Pharmaceutical by 67.8% in the 2nd quarter. Highland Capital Management LP now owns 508,822 shares of the specialty pharmaceutical company’s stock worth $12,135,000 after acquiring an additional 205,600 shares in the last quarter. 94.41% of the stock is owned by hedge funds and other institutional investors.
COLL stock opened at $15.60 on Wednesday. Collegium Pharmaceutical Inc has a twelve month low of $9.51 and a twelve month high of $29.90. The company has a debt-to-equity ratio of 3.94, a current ratio of 0.82 and a quick ratio of 0.78. The company has a market cap of $544.17 million, a P/E ratio of -6.32 and a beta of 0.24.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.02. Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The company had revenue of $73.10 million during the quarter, compared to analyst estimates of $72.21 million. The business’s revenue for the quarter was up 1930.6% on a year-over-year basis. Equities research analysts forecast that Collegium Pharmaceutical Inc will post -1.53 earnings per share for the current fiscal year.
In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction on Monday, October 15th. The stock was sold at an average price of $16.53, for a total transaction of $413,250.00. Following the sale, the director now directly owns 361,000 shares in the company, valued at approximately $5,967,330. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 13.87% of the stock is owned by company insiders.
Several brokerages have recently issued reports on COLL. Cantor Fitzgerald set a $35.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Wednesday, October 24th. Zacks Investment Research lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, October 23rd. BidaskClub raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th. HC Wainwright reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. Finally, Janney Montgomery Scott set a $27.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Monday, August 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $31.71.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/11/07/strs-ohio-increases-stake-in-collegium-pharmaceutical-inc-coll.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
See Also: Why is the ex-dividend date different from the record date?
Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical Inc (NASDAQ:COLL).
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.